The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study

Author： Macaskill E.

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.128, Iss.3, 2011-08, pp. : 725-734

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma

By Xu Zi-Zhen Wang Wen-Fang Fu Wan-Bin Wang Ai-Hua Liu Zhi-Yin Chen Li-Yun Guo Pei Li Jun-Min

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1151-1157

Informa Healthcare

Access to resources Recommend Favorite

The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts

By Behrens Diana Lykkesfeldt Anne Fichtner Iduna

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 135-144

Springer Publishing Company

Access to resources Recommend Favorite

Pre-operative chemotherapy and radiotherapy in breast cancer

By Colleoni M.

European Journal of Cancer, Vol. 35, Iss. 2, 1999-02 ,pp. : 328-328

Elsevier

Access to resources Recommend Favorite

The Value of Pre-operative Lymphoscintigraphy in Breast Cancer Treatment

By Uren R.F. Howman-Giles R.B. Thompson J.F.

European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. : 203-204

Elsevier

Access to resources Recommend Favorite

Pre-operative chemotherapy and radiotherapy in breast cancer

By Colleoni M. Nole' F. Minchella I. Noberasco C. Luini A. Orecchia A. Veronesi P. Zurrida S. Viale G. Goldhirsch A.

European Journal of Cancer, Vol. 34, Iss. 5, 1998-04 ,pp. : 641-645

Elsevier

Access to resources Recommend Favorite